Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation

G. Gahrton, H. Svensson, B. Björkstrand, J. Apperley, K. Carlson, M. Cavo, A. Ferrant, L. Fouillard, N. Gratecos, A. Gratwohl, F. Guilhot, G. Lambertenghi Deliliers, P. Ljungman, T. Masszi, D. W. Milligan, R. L. Powles, J. Reiffers, J. D. Samson, A. M. Stoppa, J. P. Vernant & 2 others L. Volin, J. Wallvik

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Twenty-five patients with multiple myeloma received bone marrow grafts (n = 24) or peripheral blood stem cells (n = 1) from twin donors. The outcome was compared in a case-matched analysis to 125 patients who underwent autologous transplantation, and 125 who underwent allogeneic transplantation. Seventeen patients (68%) receiving twin transplants entered complete remission, which was not significantly different from that of autologous (48%) or allogeneic (58%) transplants. The median overall and progression-free survival for the twins was 73 and 72 months, respectively. The overall survival tended to be better (73 vs 44 months) and the progression-free survival was significantly better (72 vs 25 months) than with autologous transplantation and both were significantly better than with allogeneic transplantation. Three of 17 patients who entered complete remission following transplantation had relapsed at follow-up. This relapse rate was significantly lower than following autologous transplantation and similar to the relapse rate with allogeneic transplantation. Only two twins died of transplant-related toxicity. Six further patients died of progressive or relapsing disease. Syngeneic transplantation in multiple myeloma appears to be the treatment of choice if a twin donor is available. A lower relapse risk than in autotransplantation may be due to reinfusion of malignant cells in some patients treated with this modality or to the presence of a graft-versus-myeloma effect in some syngeneic transplants.

Original languageEnglish
Pages (from-to)741-745
Number of pages5
JournalBone Marrow Transplantation
Volume24
Issue number7
Publication statusPublished - 1999

Fingerprint

Isogeneic Transplantation
Autologous Transplantation
Homologous Transplantation
Multiple Myeloma
Transplants
Recurrence
Disease-Free Survival
Tissue Donors
Transplantation
Bone Marrow
Survival

Keywords

  • Multiple myeloma transplants
  • Syngeneic transplantation
  • twin transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Gahrton, G., Svensson, H., Björkstrand, B., Apperley, J., Carlson, K., Cavo, M., ... Wallvik, J. (1999). Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplantation, 24(7), 741-745.

Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation. / Gahrton, G.; Svensson, H.; Björkstrand, B.; Apperley, J.; Carlson, K.; Cavo, M.; Ferrant, A.; Fouillard, L.; Gratecos, N.; Gratwohl, A.; Guilhot, F.; Lambertenghi Deliliers, G.; Ljungman, P.; Masszi, T.; Milligan, D. W.; Powles, R. L.; Reiffers, J.; Samson, J. D.; Stoppa, A. M.; Vernant, J. P.; Volin, L.; Wallvik, J.

In: Bone Marrow Transplantation, Vol. 24, No. 7, 1999, p. 741-745.

Research output: Contribution to journalArticle

Gahrton, G, Svensson, H, Björkstrand, B, Apperley, J, Carlson, K, Cavo, M, Ferrant, A, Fouillard, L, Gratecos, N, Gratwohl, A, Guilhot, F, Lambertenghi Deliliers, G, Ljungman, P, Masszi, T, Milligan, DW, Powles, RL, Reiffers, J, Samson, JD, Stoppa, AM, Vernant, JP, Volin, L & Wallvik, J 1999, 'Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation', Bone Marrow Transplantation, vol. 24, no. 7, pp. 741-745.
Gahrton G, Svensson H, Björkstrand B, Apperley J, Carlson K, Cavo M et al. Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplantation. 1999;24(7):741-745.
Gahrton, G. ; Svensson, H. ; Björkstrand, B. ; Apperley, J. ; Carlson, K. ; Cavo, M. ; Ferrant, A. ; Fouillard, L. ; Gratecos, N. ; Gratwohl, A. ; Guilhot, F. ; Lambertenghi Deliliers, G. ; Ljungman, P. ; Masszi, T. ; Milligan, D. W. ; Powles, R. L. ; Reiffers, J. ; Samson, J. D. ; Stoppa, A. M. ; Vernant, J. P. ; Volin, L. ; Wallvik, J. / Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation. In: Bone Marrow Transplantation. 1999 ; Vol. 24, No. 7. pp. 741-745.
@article{99367d74fe0b403c92e16490e09f1e63,
title = "Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation",
abstract = "Twenty-five patients with multiple myeloma received bone marrow grafts (n = 24) or peripheral blood stem cells (n = 1) from twin donors. The outcome was compared in a case-matched analysis to 125 patients who underwent autologous transplantation, and 125 who underwent allogeneic transplantation. Seventeen patients (68{\%}) receiving twin transplants entered complete remission, which was not significantly different from that of autologous (48{\%}) or allogeneic (58{\%}) transplants. The median overall and progression-free survival for the twins was 73 and 72 months, respectively. The overall survival tended to be better (73 vs 44 months) and the progression-free survival was significantly better (72 vs 25 months) than with autologous transplantation and both were significantly better than with allogeneic transplantation. Three of 17 patients who entered complete remission following transplantation had relapsed at follow-up. This relapse rate was significantly lower than following autologous transplantation and similar to the relapse rate with allogeneic transplantation. Only two twins died of transplant-related toxicity. Six further patients died of progressive or relapsing disease. Syngeneic transplantation in multiple myeloma appears to be the treatment of choice if a twin donor is available. A lower relapse risk than in autotransplantation may be due to reinfusion of malignant cells in some patients treated with this modality or to the presence of a graft-versus-myeloma effect in some syngeneic transplants.",
keywords = "Multiple myeloma transplants, Syngeneic transplantation, twin transplantation",
author = "G. Gahrton and H. Svensson and B. Bj{\"o}rkstrand and J. Apperley and K. Carlson and M. Cavo and A. Ferrant and L. Fouillard and N. Gratecos and A. Gratwohl and F. Guilhot and {Lambertenghi Deliliers}, G. and P. Ljungman and T. Masszi and Milligan, {D. W.} and Powles, {R. L.} and J. Reiffers and Samson, {J. D.} and Stoppa, {A. M.} and Vernant, {J. P.} and L. Volin and J. Wallvik",
year = "1999",
language = "English",
volume = "24",
pages = "741--745",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation

AU - Gahrton, G.

AU - Svensson, H.

AU - Björkstrand, B.

AU - Apperley, J.

AU - Carlson, K.

AU - Cavo, M.

AU - Ferrant, A.

AU - Fouillard, L.

AU - Gratecos, N.

AU - Gratwohl, A.

AU - Guilhot, F.

AU - Lambertenghi Deliliers, G.

AU - Ljungman, P.

AU - Masszi, T.

AU - Milligan, D. W.

AU - Powles, R. L.

AU - Reiffers, J.

AU - Samson, J. D.

AU - Stoppa, A. M.

AU - Vernant, J. P.

AU - Volin, L.

AU - Wallvik, J.

PY - 1999

Y1 - 1999

N2 - Twenty-five patients with multiple myeloma received bone marrow grafts (n = 24) or peripheral blood stem cells (n = 1) from twin donors. The outcome was compared in a case-matched analysis to 125 patients who underwent autologous transplantation, and 125 who underwent allogeneic transplantation. Seventeen patients (68%) receiving twin transplants entered complete remission, which was not significantly different from that of autologous (48%) or allogeneic (58%) transplants. The median overall and progression-free survival for the twins was 73 and 72 months, respectively. The overall survival tended to be better (73 vs 44 months) and the progression-free survival was significantly better (72 vs 25 months) than with autologous transplantation and both were significantly better than with allogeneic transplantation. Three of 17 patients who entered complete remission following transplantation had relapsed at follow-up. This relapse rate was significantly lower than following autologous transplantation and similar to the relapse rate with allogeneic transplantation. Only two twins died of transplant-related toxicity. Six further patients died of progressive or relapsing disease. Syngeneic transplantation in multiple myeloma appears to be the treatment of choice if a twin donor is available. A lower relapse risk than in autotransplantation may be due to reinfusion of malignant cells in some patients treated with this modality or to the presence of a graft-versus-myeloma effect in some syngeneic transplants.

AB - Twenty-five patients with multiple myeloma received bone marrow grafts (n = 24) or peripheral blood stem cells (n = 1) from twin donors. The outcome was compared in a case-matched analysis to 125 patients who underwent autologous transplantation, and 125 who underwent allogeneic transplantation. Seventeen patients (68%) receiving twin transplants entered complete remission, which was not significantly different from that of autologous (48%) or allogeneic (58%) transplants. The median overall and progression-free survival for the twins was 73 and 72 months, respectively. The overall survival tended to be better (73 vs 44 months) and the progression-free survival was significantly better (72 vs 25 months) than with autologous transplantation and both were significantly better than with allogeneic transplantation. Three of 17 patients who entered complete remission following transplantation had relapsed at follow-up. This relapse rate was significantly lower than following autologous transplantation and similar to the relapse rate with allogeneic transplantation. Only two twins died of transplant-related toxicity. Six further patients died of progressive or relapsing disease. Syngeneic transplantation in multiple myeloma appears to be the treatment of choice if a twin donor is available. A lower relapse risk than in autotransplantation may be due to reinfusion of malignant cells in some patients treated with this modality or to the presence of a graft-versus-myeloma effect in some syngeneic transplants.

KW - Multiple myeloma transplants

KW - Syngeneic transplantation

KW - twin transplantation

UR - http://www.scopus.com/inward/record.url?scp=0032862958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032862958&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 741

EP - 745

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -